The CAD+ patients were also more likely to be receiving statin therapy (39% vs 18%, P = 0.024), and ACE inhibitor or angiotensin receptor blocker therapy (42% vs 21%, P = 0.028). The gene discussed is ACE; the disease is coronary artery disorder.